FDA decision on experimental Alzheimer's drug expected this week

FDA decision on experimental Alzheimer's drug expected this week

Even if the FDA offers accelerated approval of the drug, it will still be studied in more robust trials.

FDA decision on experimental Alzheimer's drug expected this week

The US Food and Drug Administration could decide this week whether to grant accelerated approval to the experimental dementia drug lecanemab, according to Eisai and Biogen, the companies that make

FDA decision on experimental Alzheimer's drug expected this week

By Jacqueline Howard, CNN The US Food and Drug Administration could decide this week whether to grant accelerated approval to the experimental dementia drug lecanemab, according to Eisai and Biogen, the companies that make the drug. Lecanemab — one of the first experimental dementia drugs to appear to slow the progression of cognitive decline —

FDA decision on experimental Alzheimer's drug expected this week

The US Food and Drug Administration could decide this week whether to grant accelerated approval to the experimental dementia drug lecanemab, according to Eisai and Biogen, the companies that make

FDA decision on experimental Alzheimer's drug expected this week

The US Food and Drug Administration could decide this week whether to grant accelerated approval to the experimental dementia drug lecanemab, according to Eisai and Biogen, the companies that make

FDA decision on experimental Alzheimer’s drug expected this week

(CNN) — The US Food and Drug Administration could decide this week whether to grant accelerated approval to the experimental dementia drug lecanemab, according to...